The overall objective of the Core Clinical Laboratory (CCL) are to provide resources, skilled laboratory technology, and specialized laboratory parameters that are appropriate to monitor and assess the activity of new cytotoxic and immune modulating anti-neoplastic agents. The unit provides a variety of reliable assay methodologies with a high level of quality control, and then supplies the analyzed data to the study investigator. The CCL provides the laboratory support for clinical trials of cytotoxic modalities and trials have pharmacodynamic endpoints. In addition, the CCL supports trials the require assessment of multiple parameters ranging from specialized tests for patient eligibility to quality control of specialized therapeutic modalities. This multiple function evolved from cancer center initiated studies with combination immune- modulating and cytotoxic therapies. The CCL has broadened its function, now providing the appropriate laboratory specialized clinical correlates for the monitoring of these novel approaches to cancer treatment. The primary users of the shared resource are Cancer Center members who need support for their peer reviewed research projects which involved the specialized assays available in the CCL.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-21
Application #
6101773
Study Section
Project Start
1999-05-10
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Gupta, Ankit; Xu, Jing; Lee, Shirley et al. (2018) Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol 14:895-900
Marié, Isabelle J; Chang, Hao-Ming; Levy, David E (2018) HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med 215:3194-3212
Evensen, Nikki A; Madhusoodhan, P Pallavi; Meyer, Julia et al. (2018) MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103:830-839
Lee, Hyun-Wook; Park, Sung-Hyun; Weng, Mao-Wen et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc Natl Acad Sci U S A 115:E1560-E1569

Showing the most recent 10 out of 1170 publications